Combined use of farnesil transferase inhibitor and an antineoplastic Agent and / or radiation therapy for the treatment of proliferative Diseases

摘要

(a) refers to the use of an inhibitor of the transferase farnesil (FPT) as benzocicloheptapiridina tricyclic FUSED ring, oligopeptide, Mimetic peptide.Farnesilado Mimetic Peptide, or a derivative farnesilado; (b) an antineoplastic Agent, which affects microtubules as uracil Mustard, chlormethine, Melphalan, cyclophosphamide, ifosfamide,Chlorambucil, pipobromano, trietilenemelamina, trietilentiofosforamina, Busulfan, carmustine, Lomustine, streptozocin, dacarbazine, 5-fluorouracil, methotrexate, cytarabine, fudr,6-mercaptopurine, pentostatin, FLUDARABINE PHOSPHATE, temozolomide, vindesine, bleomycin, vinblastine, vincristine, dactinomycin, daunorubicin, doxorubicin, gemcitabine, paclitaxel, TAXOTERE,Among others; when the FPT inhibitor formula, where X is Halo; and ` h 'is H, - coor; R' is C1 C12 alkyl, phenyl, alkylaryl, 2 - piperidilo,Among others, the chemotherapy Agent is not epipodofillotoxinas Vinca Alkaloid, anthracycline Antibiotics, actinomycin D,Among others, the combination may be useful in the treatment of proliferative diseases such as Lung Cancer, pancreatic cancer, colon cancer, melanoma, Leukemia, Myeloid,Follicular thyroid cancer, carcinoma of gallbladder, glioma, myelodysplastic syndrome, Breast Cancer, Prostate Cancer